Table 2.
Patient characteristics
| No complications | Non-cardiac complications | P value | |
|---|---|---|---|
| n | 117 | 67 | |
| Age (median [IQR]) years | 74 [69, 78] | 75 [70, 80] | 0.576 |
| Sex, n (%) male | 86 (73) | 48 (71) | 0.919 |
| BMI (median [IQR]) kg m−2 | 26 [24, 30] | 25 [24, 29] | 0.333 |
| American Society of Anaesthesiologists classification | 0.333 | ||
| 2 | 27 (23) | 11 (16) | |
| 3 | 88 (75) | 53 (79) | |
| 4 | 2 (1) | 3 (4) | |
| Surgical procedure | |||
| Open aortic surgery | 13 (11) | 11 (16) | 0.423 |
| Peripheral vascular surgery | 58 (50) | 40 (60) | 0.241 |
| Endovascular aortic surgery | 46 (39) | 16 (24) | 0.049 |
| Anaesthesia technique | |||
| General anaesthesia | 40 (34) | 31 (46) | 0.144 |
| Regional anaesthesia | 79 (67) | 39 (58) | 0.268 |
| Intra-operative haemorrhage > 500 ml | 24 (20) | 21 (31) | 0.143 |
| Comorbidities | |||
| Smoker | 38 (32) | 25 (37) | 0.615 |
| Hypertension | 101 (86) | 57 (85) | 0.989 |
| Diabetes, no insulin therapy | 26 (22) | 14 (20) | 0.957 |
| Diabetes, with insulin therapy | 14 (12) | 11 (16) | 0.547 |
| Chronic obstructive pulmonary disease | 20 (17) | 10 (14) | 0.841 |
| Heart failure | 19 (16) | 14 (20) | 0.571 |
| Ischemic heart disease | 44 (37) | 21 (31) | 0.461 |
| Stroke or TIA | 10 (8) | 10 (14) | 0.284 |
| Cancer | 11 (9) | 10 (14) | 0.383 |
| Chronic kidney disease | 21 (18) | 8 (11) | 0.374 |
| Biomarker, pre-operative | |||
| Creatinine (median [IQR]) μmol l-1 | 85 [72, 101] | 82 [68, 98] | 0.298 |
| NT-proBNP (median [IQR]) ng l-1 | 219 [97, 537] | 231 [121, 539] | 0.440 |
| hs-cTnT (median [IQR]) ng l-1 | 13 [9, 18] | 13 [10, 18] | 0.584 |
| Duration of surgery (median [IQR]) minutes | 155 [118, 231] | 230 [163, 299] | <0.001 |
| Group hyperoxiaa | 61 (52) | 29 (43) | 0.316 |
All results are presented as n ( %), unless otherwise stated. IQR = interquartile range
Abbreviations: NT-proBN P N-terminal-pro-B-type natriuretic peptide, hs-cTnT High-sensitivity cardiac Troponin T
aGroup hyperoxia (FiO2 > 0.5) or normoxia (FiO2 = 0.21)